
Trump withdraws FDA commissioner nominee Heidi Overton, extending a leadership gap that leaves review and launch timelines uncertain for sponsors.
Responding to the development of more novel therapies and fast-track designations means being equipped with the right processes and resources to support expedited approvals right from the beginning of process development.






